Nakahara H, Yoshikawa H, Takaoka K, Ono K
Bone. 1986;7(3):229-33. doi: 10.1016/8756-3282(86)90022-0.
The effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on ectopic bone formation were studied qualitatively and quantitatively in an experimental system for ectopic bone formation induced by murine osteosarcoma-derived bone-inducing substance. At a low dose of EHDP (3 mg/kg per day i.p.), histologic sequelae of ectopic bone formation were normal, and the size of the induced bone mass was unaffected. At a high dose of EHDP (30 mg/kg per day i.p.), an unmineralized bone matrix with hematopoietic bone marrow was formed without evidence of retardation. This osteoid tissue showed no radiologic and histologic evidence of mineralization during the period of EHDP administration. When EHDP was withdrawn, its inhibitory effect on mineralization was reversed. The induced bone mass was almost the same size as that in controls. These results suggest that EHDP might not prevent ectopic bone matrix formation, but its mineralization and withdrawal of EHDP might lead to the formation of a normal bone similar in size to that formed without EHDP treatment.
在由鼠骨肉瘤衍生的骨诱导物质诱导异位骨形成的实验系统中，对乙烷 -1- 羟基 -1,1- 二膦酸盐（EHDP）对异位骨形成的影响进行了定性和定量研究。在低剂量的 EHDP（每天腹腔注射 3 毫克 / 千克）时，异位骨形成的组织学后遗症正常，诱导骨块的大小未受影响。在高剂量的 EHDP（每天腹腔注射 30 毫克 / 千克）时，形成了带有造血骨髓的未矿化骨基质，且没有延迟的迹象。在给予 EHDP 期间，这种类骨质组织没有显示出矿化的放射学和组织学证据。当停用 EHDP 时，其对矿化的抑制作用被逆转。诱导的骨块大小几乎与对照组相同。这些结果表明，EHDP 可能不会阻止异位骨基质的形成，但其矿化以及停用 EHDP 可能导致形成与未用 EHDP 处理时大小相似的正常骨。
